Published in Cancer Weekly, November 2nd, 2004
The goals of this trial are to evaluate the safety and pharmacokinetics of Hematide and to determine its effect on reticulocytes and hemoglobin. Results of this trial are expected in early 2005, and, if positive, will allow Affymax to enter into phase II safety and efficacy trials later that year.
Hematide is a synthetic peptide ESA that has been shown to stimulate the production of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.